Partner with the British Cardiovascular Society to Drive Cardiovascular Innovation
The British Cardiovascular Society (BCS) values strong industry collaborations that are vital to advancing cardiology through innovation, research, treatment, and education. Our partnerships support our annual conference, educational initiatives, and the wider cardiovascular community, benefiting clinicians, researchers, and patients.
By becoming a BCS Principal Partner, your organisation can:
- Foster mutual understanding and cooperation within a transparent governance framework.
- Collaborate on impactful projects that advance cardiovascular health and innovation.
- Receive exclusive access to bi-annual corporate partner briefings and roundtable discussions.
- Opportunities for direct collaboration on areas of shared interest.
- A platform to engage with key opinion leaders and raise critical industry issues.
- Participation in high-profile initiatives, boosting visibility and engagement.
Join us as a BCS Partner and help shape the future of cardiovascular health.
For more details, contact [email protected]
Partnership Benefits
Exclusive Priority for BCS Academy and Educational Initiatives
Ensure visibility and engagement among BCS members in flagship activities and receive priority invitations to support and participate in educational initiatives
Bi-annual One-to-One Meetings with BCS Leadership
Gain direct access to the BCS President, Officers, and CEO to discuss partnership progress and explore new initiatives
Bi-annual Corporate Partner Briefings and Round Table Discussions
Participate in exclusive events for high-level industry engagement and knowledge sharing
Discounted Stand Prices and Free Hot Topic at Conference
Benefit from reduced costs for BCS conference stands, priority for symposiums, and complimentary access to a Free Hot Topic session
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide.
With a proud 100-year heritage in advancing UK science, today AstraZeneca is the UK’s leading biopharmaceutical company. The company is based in five different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,700 employees work in research and development, manufacturing, supply, sales, and marketing. We supply around 36 different medicines to the NHS.
For more information, please visit www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to advancing a portfolio of innovative treatments. Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds are in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritises targets and pathways with the potential to impact the way that cardiovascular diseases are treated.
RP-UN-CAR-GB-0192 | September 2024
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health.
Learn more at www.boehringer-ingelheim.com/uk
Count on us to keep them in the moment
At Daiichi Sankyo UK, we create and supply innovative products to help the NHS to deliver better patient care in the fields of cardiovascular disease and oncology.
Our mission is to contribute to the enrichment of quality of life through the discovery and delivery of innovative medicines that address diverse and unmet medical needs.
Twitter: x.com/daiichisankyouk
LinkedIn www.linkedin.com/company/daiichi-sankyo-uk-ltd
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most.
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.
In the UK, we champion health and lives through pioneering NHS partnerships, innovative collaborations and a clear focus on the greatest healthcare challenges we all face. We are where science meets hope.
Bold thinking. Bolder actions. We are Medtronic. We lead global healthcare technology and boldly attack the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.
As a leading health technology company, we’re working to make life better by providing future focused innovation that cares for both people and the planet. Working with health providers across the UK and Ireland, our innovations are giving healthcare professionals more time to focus on what matters most – patients – acting responsibility and sustainably to ensure we provide care with impact.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. To learn more about our commitments, please visit us at www.pfizer.co.uk
ZOLL Cardiac Management Solutions offers a unique portfolio of novel technologies designed to deliver better insights and better outcomes in cardiac patient care, including the LifeVest wearable cardioverter defibrillator (WCD).
In 2006, the Cardiac Management Solutions business became a part of ZOLL Medical Corporation, which was acquired by Asahi Kasei in 2012. ZOLL develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnoea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions.